March 24, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, the industry leader in aesthetics globally, demonstrates how to elevate the patient experience and achieve optimal treatment ...

Four expert-led educational events with Allergan Medical Institute (AMI), Science of Aging TM and Allergan Aesthetics (AA) Global Medical Affairs AMI symposia will focus on a new Allergan ...

Four expert-led educational events with Allergan Medical Institute (AMI), Science of AgingTM and Allergan Aesthetics (AA) Global Medical Affairs AMI symposia will focus on a new Allergan ...

AbbVie will now lead development of GUB014295. Carrie Strom, president, global Allergan aesthetics at AbbVie, discussed the obesity market on the drug developer’s earnings call in January.

US drugmaker AbbVie has agreed to buy struggling Allergan in a $63 billion deal that continues a slew of multibillion dollar takeovers in the biopharma sector this year. AbbVie is stumping up more ...

The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox). In light of the recent options history for AbbVie, it's now appropriate to focus on the ...

Four expert-led educational events with Allergan Medical Institute (AMI), Science of Aging TM and Allergan Aesthetics (AA) Global Medical Affairs AMI symposia will focus on a new Allergan Aesthetics ...

AbbVie has filed a lawsuit against Genmab, accusing the Danish drugmaker of being “intentionally and willfully blind” to the theft of trade secrets. Genmab has vowed to “vigorously defend ...

As previously reported, Erste Group upgraded AbbVie (ABBV) to Buy from Hold. The firm notes AbbVie recently confirmed its expectations for annual sales growth in the high single-digit percentage ...

Erste Group upgraded AbbVie (ABBV) to Buy from Hold. Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor analyses. Published first on TheFly ...

Allergan is selling rights to its Crohn’s disease drug brazikumab back to AstraZeneca in a move to satisfy regulators ahead of its merger with AbbVie. The two companies have axed an R&D ...